WO2008052087A1 - Dérivés de chromane et leurs utilisations - Google Patents

Dérivés de chromane et leurs utilisations Download PDF

Info

Publication number
WO2008052087A1
WO2008052087A1 PCT/US2007/082451 US2007082451W WO2008052087A1 WO 2008052087 A1 WO2008052087 A1 WO 2008052087A1 US 2007082451 W US2007082451 W US 2007082451W WO 2008052087 A1 WO2008052087 A1 WO 2008052087A1
Authority
WO
WIPO (PCT)
Prior art keywords
disorder
hydrogen
independently hydrogen
compound
formula
Prior art date
Application number
PCT/US2007/082451
Other languages
English (en)
Inventor
Gary Paul Stack
William Demaio
John Chuck Lem Erve
Karthick Vishwanathan
Jianyao Wang
Sarvesh Vashishtha
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth filed Critical Wyeth
Publication of WO2008052087A1 publication Critical patent/WO2008052087A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/66—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La présente invention concerne des composés qui sont des agonistes ou des agonistes partiels du sous-type 2C des récepteurs de la sérotonine du cerveau. De tels composés ou des sels pharmaceutiquement acceptables de ceux-ci répondent à la formule (I) : dans laquelle A, R1, R2, R3, R4, Rf, Rg, Ra, Rb, Rc, Rd, Re, Rx, Ry, m, n et chaque groupe == sont chacun tels que définis ici. De tels composés et des compositions de ceux-ci sont utilisables pour traiter divers troubles du système nerveux central tels que la schizophrénie.
PCT/US2007/082451 2006-10-24 2007-10-24 Dérivés de chromane et leurs utilisations WO2008052087A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85385506P 2006-10-24 2006-10-24
US60/853,855 2006-10-24

Publications (1)

Publication Number Publication Date
WO2008052087A1 true WO2008052087A1 (fr) 2008-05-02

Family

ID=39168425

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/082451 WO2008052087A1 (fr) 2006-10-24 2007-10-24 Dérivés de chromane et leurs utilisations

Country Status (5)

Country Link
AR (1) AR063375A1 (fr)
CL (1) CL2007003043A1 (fr)
PE (1) PE20080894A1 (fr)
TW (1) TW200823186A (fr)
WO (1) WO2008052087A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009063992A1 (fr) 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited Dérivé de pyridine condensé et son utilisation
WO2011071136A1 (fr) 2009-12-11 2011-06-16 アステラス製薬株式会社 Agent thérapeutique pour la fibromyalgie
WO2012030953A1 (fr) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Agonistes du récepteur 5-ht2c dans traitement de troubles améliorés par réduction du taux de noradrénaline
WO2015066344A1 (fr) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. Agonistes du récepteur 5-ht2c et compositions et procédés d'utilisation
EP3878447A1 (fr) 2020-03-11 2021-09-15 InterAx Biotech AG Antagonistes du récepteur bêta adrénergique

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5318988A (en) * 1991-10-28 1994-06-07 Bayer Aktiengesellschaft 2-aminomethyl-chromans
WO1995005383A1 (fr) * 1993-08-19 1995-02-23 Janssen Pharmaceutica N.V. Derives de dihydrobenzopyrane vasoconstricteurs
WO2003029239A1 (fr) * 2001-10-04 2003-04-10 Wyeth Derives de chromane et de benzofurane utilises comme ligands 5-hydroxytryptamine-6
WO2005044812A1 (fr) * 2003-10-24 2005-05-19 Wyeth A Corporation Of The State Of Delaware Derives de dihydrobenzofuranyle alcanamine servant d'agonistes de 5ht2c
WO2006116165A1 (fr) * 2005-04-22 2006-11-02 Wyeth Derives de chromane et de chromene, et leurs utilisations

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5318988A (en) * 1991-10-28 1994-06-07 Bayer Aktiengesellschaft 2-aminomethyl-chromans
WO1995005383A1 (fr) * 1993-08-19 1995-02-23 Janssen Pharmaceutica N.V. Derives de dihydrobenzopyrane vasoconstricteurs
WO2003029239A1 (fr) * 2001-10-04 2003-04-10 Wyeth Derives de chromane et de benzofurane utilises comme ligands 5-hydroxytryptamine-6
WO2005044812A1 (fr) * 2003-10-24 2005-05-19 Wyeth A Corporation Of The State Of Delaware Derives de dihydrobenzofuranyle alcanamine servant d'agonistes de 5ht2c
WO2006116165A1 (fr) * 2005-04-22 2006-11-02 Wyeth Derives de chromane et de chromene, et leurs utilisations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AMY R. WATSON: "Synthesis of 8-Phenyl-gamma-benzopyrone and a gamma-Phenathropyrone", JOURNAL OF CHEMICAL SOCIETY, vol. 109, 1916, pages 303 - 307, XP002473565 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009063992A1 (fr) 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited Dérivé de pyridine condensé et son utilisation
EP2789338A2 (fr) 2007-11-15 2014-10-15 Takeda Pharmaceutical Company Limited Dérivé de pyridine condensé et son utilisation
WO2011071136A1 (fr) 2009-12-11 2011-06-16 アステラス製薬株式会社 Agent thérapeutique pour la fibromyalgie
WO2012030953A1 (fr) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Agonistes du récepteur 5-ht2c dans traitement de troubles améliorés par réduction du taux de noradrénaline
WO2015066344A1 (fr) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. Agonistes du récepteur 5-ht2c et compositions et procédés d'utilisation
EP3878447A1 (fr) 2020-03-11 2021-09-15 InterAx Biotech AG Antagonistes du récepteur bêta adrénergique

Also Published As

Publication number Publication date
PE20080894A1 (es) 2008-08-28
AR063375A1 (es) 2009-01-28
TW200823186A (en) 2008-06-01
CL2007003043A1 (es) 2008-05-30

Similar Documents

Publication Publication Date Title
US7402687B2 (en) Dihydrobenzofuran derivatives and uses thereof
US7368477B2 (en) Benzofuranyl alkanamine derivatives and uses thereof
US20060258739A1 (en) Dihydrobenzofuran derivatives and uses therof
WO2008052086A1 (fr) Dérivés de benzodioxane et leurs utilisations
US7365095B2 (en) Chromane and chromene derivatives and uses thereof
US20060241172A1 (en) Benzodioxane and benzodioxolane derivatives and uses thereof
US20100035871A1 (en) Benzoxazine derivatives and uses thereof
WO2008052087A1 (fr) Dérivés de chromane et leurs utilisations
US20100160411A1 (en) Benzoxathiine and benzoxathiole derivatives and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07844591

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07844591

Country of ref document: EP

Kind code of ref document: A1